跳至主要内容
临床试验/NCT03243292
NCT03243292已完成不适用

Ten Year Follow-up of Subjects From 3 Landmark Randomized Controlled Bronchial Thermoplasty (BT) Studies

Boston Scientific Corporation17 个研究点 分布在 5 个国家目标入组 192 人开始时间: 2017年12月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
192
试验地点
17
主要终点
Primary Effectiveness: Endpoints at 10 or more years following the subjects' last BT procedure; Asthma Exacerbations, ER Visits, Hospitalizations, and respiratory Serious Adverse Events.

研究概览

简要总结

To confirm the long-term efficacy and safety of Bronchial Thermoplasty (BT) at 10 years follow-up or beyond in subjects previously enrolled in any of the following Boston Scientific-sponsored, controlled pre-approval studies: AIR, RISA and AIR2.

详细描述

Compare rates of severe asthma exacerbations of subjects during the first and fifth year after BT treatment with the proportion of subjects who experience severe asthma exacerbations during the 12 months period prior to enrollment.

Compare baseline HRCT scans from subjects from the AIR2 study that enroll in BT 10+ study to examine if there are any clinically significant post-treatment respiratory changes following BT defined as bronchiectasis or bronchial stenosis.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Severe asthma exacerbation or chest infection in the past 4 weeks. Subject entry into this study should be delayed until free from severe asthma exacerbation or chest infection for a minimum of 4 weeks.

结局指标

主要结局

Primary Effectiveness: Endpoints at 10 or more years following the subjects' last BT procedure; Asthma Exacerbations, ER Visits, Hospitalizations, and respiratory Serious Adverse Events.

时间窗: The BT 10+ study's single visit must occur 10 years after the subject's last BT procedure.

Durability of the treatment effect by comparing the proportion of subjects who experience severe asthma exacerbations during the first and fifth years after BT treatment with the proportion of subjects who experience severe asthma exacerbations during the 12 month period prior to the BT 10+ study visit.

Primary Safety Endpoint: Absence of clinically significant post-treatment respiratory changes from Baseline (pre-Bronchial Thermoplasty) CT.

时间窗: The BT 10+ study's single visit must occur 10 years after the subject's last BT procedure.

Following BT, defined as bronchiectasis or bronchial stenosis, as confirmed by Pulmonary Volumetric HRCT scan at the BT 10+study visit in those3 subjects who had baseline Volumetric HRCT scan in the AIR2 study. Baseline and 10+ year HRCTs are to be read by an independent radiologist and also assessed by an independent pulmonologist.

次要结局

  • rates of emergency room visits for respiratory adverse events(One day visit)
  • Rates of Respiratory Serious Adverse Events (SAEs)(One day visit)
  • Proportion of subjects with hospitalizations for respiratory adverse events(One day visit)
  • Severe asthma exacerbation rates exacerbations(One day visit)
  • Severe asthma exacerbation rates year(One day visit)
  • Rates of hospitalizations for respiratory adverse events(One day visit)
  • Severe asthma exacerbation rates subject(One day visit)
  • proportion of subjects with emergency room visits for respiratory adverse events(One day visit)
  • Proportion of subjects with respiratory SAEs)(One day visit)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (17)

Loading locations...

相似试验